Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CyPep 1 - Cytovation

Next Previous
Drug Profile

CyPep 1 - Cytovation

Alternative Names: CyPep 1; CyPep-H1

Latest Information Update: 18 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cytovation
  • Developer Centre for Human Drug Research; Cytovation; Haukeland University Hospital; MSD Pharmaceuticals
  • Class Antineoplastics; Peptides; Skin disorder therapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Malignant melanoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer
  • Phase I Liver disorders
  • Preclinical Recurrent respiratory papillomatosis
  • No development reported Skin disorders; Warts

Most Recent Events

  • 20 Oct 2023 Pharmacodynamics data from a preclinical study in Solid tumours presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
  • 13 Oct 2023 9400608: Updated KDM, added efficacy and safety data and relevant HE
  • 11 Oct 2023 Interim adverse events and efficacy data from a phase I/IIa CICILIA basket trial in Solid tumors released by Cytovation
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top